Search
2 articles for “Antibody–Drug Conjugates (ADCs)”
-
Non-Small Cell Lung Cancer: Types, Pathogenesis, Diagnosis, and Novel Therapeutic Strategies
Abstract: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for over 85% of all cases globally. It remains one of the primary causes of cancer-related death due to its rapid progression, few early symptoms, and late detection. The three main forms of non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma; each has a unique histology, prognosis, and response to …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 2, 2026 Read article
-
Monoclonal antibodies in targeted cancer therapy advances, resistance mechanisms, and next-gen formats (Bispesifics, ADCs)
Abstract: Breast cancer is one of the leading causes of cancer-related morbidity and death worldwide, which emphasizes the need for more effective and focused treatment strategies. antibody-mediated drug delivery techniques. Specifically, antibody–drug conjugates (ADCs) have emerged as a potential approach that combines the specificity of monoclonal antibodies with the potent cytotoxicity of anticancer drugs. By selectively targeting tumor-associated antigens, ADCs enhance drug accumulation within cancer cells while minimizing systemic toxicity associated …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 17, Issue 2, 2026 Read article